

REMARKS/ARGUMENTS

Applicants respectfully request reconsideration and allowance of this application in view of the amendments above and the following comments.

At the outset, Applicants acknowledge with appreciation the Examiner's indication that claims 2-8 and 14-16 are allowable in substance.

Claims 1, 10 and 13 were rejected under 35 USC § 102(b) as being anticipated by, and under 35 USC § 103(a) as being obvious over Li et al., Chinese Patent No. 1122806A. The Examiner relies on compound 31 of the reference. In response, Applicants point out that claim 1 has been amended in accordance with the instant specification at page 9, lines 24-26. Such amendment excludes the 1,3-diazinyl substituent of Li et al, and, thus, there is no anticipation and no obviousness either.

The minor change in claim 8 also is not believed to introduce new matter.

Applicants believe that the foregoing constitutes a bona fide response to all outstanding objections and rejections.


Applicants also believe that this application is in condition for immediate allowance. However, should any issue(s) of a minor nature remain, the Examiner is respectfully requested to telephone the undersigned at telephone number (212) 808-0700 so that the issue(s) might be promptly resolved.

Early and favorable action is earnestly solicited.

Respectfully submitted,

NORRIS MCLAUGHLIN & MARCUS, P.A.

By


Kurt G. Briscoe

Attorney for Applicant(s)

Reg. No. 33,141

875 Third Avenue - 18th Floor

New York, New York 10022

Phone: (212) 808-0700

Fax: (212) 808-0844

USSN 10/506,926

8

Amendment in response to Office Action dated November 4, 2005

100717-647 R111 Amdt as Filed